Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Date of Report: December 3, 2024
Reporting Period: Events occurring on December 2 and December 3, 2024.
The Company is a biopharmaceutical firm focused on developing therapies for kidney injury and disease. This filing reports a material definitive agreement regarding a warrant exercise inducement and the FDA acceptance of an Investigational New Drug (IND) application.
Key Financial Metrics and Transaction Details
This filing does not contain standard periodic financial statements (revenue, profit, or cash flow). However, it discloses specific transaction metrics:
- Gross Proceeds: Approximately $4.1 million from the exercise of existing Class E warrants.
- Transaction Fees: A cash fee of approximately $325,123 payable to Roth Capital Partners, LLC.
- Warrant Exercise Price: $1.00 per share for the 4,064,040 existing warrants exercised.
- Inducement Warrants Issued:
- 4,064,040 Class F Warrants (2-year term, cashless exercise option available).
- 6,096,060 Class G Warrants (5-year term, antidilutive provisions).
Material Changes and Events
Warrant Exercise Inducement: The Company entered into agreements with holders of existing warrants to exercise them at $1.00 per share. In exchange, holders received new Class F and Class G warrants. The transaction was structured as an at-market transaction under Nasdaq rules.
Regulatory Milestone: On December 2, 2024, the Company announced FDA acceptance of the Gemini IND application, a prerequisite for initiating clinical trials.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds: Net proceeds from the warrant exercise are designated for:
- Conducting a planned Phase 1b clinical study for GEM-AKI in CKD patients.
- Necessary preclinical work for GEM-CKD.
- Continued development of other products and therapies.
- Funding working capital and general corporate purposes.
Outlook: The filing indicates a strategic focus on advancing clinical development for its GEM-AKI, GEM-CKD, and GEM-PSI product candidates.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting the $325,123 advisory fee.
- Confirm the timeline for obtaining stockholder approval required to make the Class F and Class G Inducement Warrants exercisable.
- Monitor the status of the Gemini IND application following FDA acceptance to track the initiation of clinical trials.
- Review the upcoming Form S-3 resale registration statement to be filed within 20 days of closing.